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model were obtained from published clinical trials and were
complemented with Mexican expert opinion surveys. Effective-
ness measure was the number of patients with articular pain con-
trolled without adverse events (peptic ulcers, gastrointestinal
bleeding, and others). The analysis was conducted from the
healthcare payer’s perspective. Resource use and costs were
obtained from hospital records and Mexican ofﬁcial databases.
Threshold and probabilistic sensitivity analysis was performed
and acceptability curves were constructed. RESULTS: The model
indicates that the use of celecoxib could lead to the avoidance of
a signiﬁcant number of adverse events associated to NSAIDs and
acetaminophen. Celecoxib showed on the six-months period
similar (p = 0.52) expected costs per patient (US$609.8) than the
treatment with NSAIDs (US$615.6) and lower costs (p < 0.01)
compared with acetaminophen (US$656.7). On the other hand,
celecoxib was associated with higher effectiveness (371 patients,
CI 95% 255–452) followed by NSAIDs and acetaminophen (274
and 270 patients, respectively). Results were robust to Monte
Carlo ﬁrst order sensitivity analysis. Acceptability curves showed
the same results with a mean of 44.5% of certainty. CONCLU-
SIONS: Despite its higher cost in the Mexican market, celecoxib
was cost—effective for the management of articular pain in
patients with ostheoarthritis.
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OBJECTIVES: Clinical studies such as REFLEX established the
efﬁcacy of rituximab (RTX) in patients with rheumatoid arthri-
tis (RA) who have had an inadequate response to anti-TNF
therapy. This analysis evaluated the cost-effectiveness of treating
such patients with RTX across different EU countries.
METHODS: Our cost-effectiveness model assessed RA treat-
ments in a real-life setting based on practices in Germany, Italy,
Spain, France, and the UK. The model is based on ACR response
rates for RTX and current treatment options (adjusted for the
different study populations), complemented with epidemiologi-
cal data from observational studies. It simulates a cohort of
10,000 patients who have failed to respond to anti-TNF therapy.
Baseline patient characteristics were from the REFLEX study.
For each country, the cost-effectiveness of providing RTX either
as an additional treatment or an alternative to a second-line bio-
logic DMARD was examined using a treatment duration for bio-
logical therapy (in combination with methotrexate) of up to 4.25
years. QALYs were mapped from a disease severity measure
(HAQ score) and resource utilization data were UK or German
registry data. The model included costs related to drug therapy
(including administration and monitoring), palliative care and
reduced productivity (indirect costs) (2004–5 Euros [€]). Costs
and beneﬁts were discounted at 3.5% per annum. RESULTS:
Using RTX resulted in lower average annual cost compared to
any of the anti-TNF treatments. The cost per QALY (direct
medical cost) was in the range of €18,000 to €23,000 across all
health care systems. When RTX is replacing a treatment option
in the current treatment sequence, average annual treatment
costs can be reduced. CONCLUSIONS: This pan-European
analysis shows that adding RTX to the therapeutic armamen-
tarium for patients with RA who respond inadequately to anti-
TNF therapy is highly cost-effective, with an incremental cost
per QALY gained that is favourable compared to other disease-
modifying, biological therapies.
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OBJECTIVE: To perform a cost-effectiveness analysis on TNF-
alpha inhibitors (Anti-TNFa) for treatment of Ankylosing
Spondylitis (AS) in comparison to standard therapy alone from
a societal perspective. METHODS: Decision-tree analysis was
performed to estimate the incremental cost-effectiveness ratio
(ICER) for Anti-TNFa treatments in AS patients. All model para-
meters (e.g. cost, response rates, EQ-5D derived utility values,
etc.) were obtained from published literature and/or expert
opinion. Total cost included cost relating to illness, drug, drug-
related side effects, chest radiography for tuberculosis (TB)
screening, TB treatment for TB+ patients, and annual drug mon-
itoring. Cost of Illness (COI) included direct costs (e.g. total
ambulatory/hospital care, diagnostic testing, assistive devices,
travel to visits, nonallopathic treatments, etc.) and indirect costs
(e.g. short-term leave, paid work disability, etc.). Informal care-
giver cost was not included. Cost was linked to BASDAI and
BASFI scores reported in the Kobelt study by performing OLS
regression. The two resulting models (BASDAIcost and BASFIcost)
with regression equations: logCOST = 3.168 + 0.145455*BASFI
and logCOST = 3.594667 + 0.049879 * BASDAI, respectively,
were then used to estimate COI. Univariate Sensitivity Analysis
was conducted to estimate percent changes in ICER from the
base-case using parameters such as response rates, discount rates,
and discontinued rates. QALYs and cost were discounted at 3%.
RESULTS: The BASDAIcost model revealed an ICER of $46,990.
Meanwhile, the BASFIcost model had an ICER of $38,636. In the
UA analysis, the ICERs in the BASDAIcost and BASFIcost models
varied from $36,068 to $66,472 and $22,766 to $66,539,
respectively. Both models were sensitive to changes in response
rates. However, overall, the ASDAIcost model was more robust
than the BASFIcost model. CONCLUSIONS: In the UK, the
threshold level recommended by NICE for treatment was about
£30,000/QALY. This translates into US$53,589. Using the NICE
threshold, Anti-TNFa treatment for AS is cost-effective from the
societal perspective.
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OBJECTIVES: To provide a cost-efﬁcacy (CE) analysis from a
third-party payer perspective of etanercept and inﬂiximab, com-
pared to placebo in psoriatic arthritis patients. METHODS: An
Excel based CE model was developed to estimate number needed
to treat (NNT) and cost per successful outcome using published,
24-week CE data for etanercept and inﬂiximab. Dosing infor-
mation was obtained from product labels. Plan-speciﬁc drug
costs, and administration costs were utilized in the model. 
The cost of adverse events was not included in the model. The
NNT and cost per successful outcome were estimated using 
the American College of Rheumatology scores (ACR 20, 50, 70),
the Psoriasis Area and Severity Index scores (PASI 50, 75, 90),
and a combination of ACR and PASI scores. RESULTS: Based
on the ACR scores, the NNT ranges were 2.6 to 4.0 for inﬂix-
imab and 2.7 to 12.5 for etanercept. Using the PASI score, the
NNT ranges were 1.5 to 2.6 for inﬂiximab and 3.5 to 33.3 for
